Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations
Neal Shore, MD, FACS, discusses the safety profiles reported across the nadofaragene firadenovec, SunRISe-1, and NURE-COMBO trials, highlighting any unexpected toxicities observed with these novel therapies for non-muscle-invasive and muscle-invasive bladder cancer. Additionally, he reviews key limitations of the study designs or patient populations that may impact the interpretation and generalizability of the results from these trials.
Video content above is prompted by the following question(s):
- Discuss the safety profiles reported across these three trials. Were there any new or unexpected toxicities observed with the novel therapies compared to standard treatments?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- BCMA-Targeted Bispecific Antibodies: Navigating the New Frontier of Myeloma
September 17th 2025
- Linvoseltamab: A New Horizon for Relapsed Myeloma
September 17th 2025